Y
Yuki Takamatsu
Researcher at National Institutes of Health
Publications - 48
Citations - 580
Yuki Takamatsu is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 26 publications receiving 261 citations. Previous affiliations of Yuki Takamatsu include University of Marburg.
Papers
More filters
Journal ArticleDOI
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Shin ichiro Hattori,Nobuyo Higashi-Kuwata,Hironori Hayashi,Srinivasa Rao Allu,Jakka Raghavaiah,Haydar Bulut,Debananda Das,Brandon J. Anson,Emma K. Lendy,Yuki Takamatsu,Nobutoki Takamune,Naoki Kishimoto,Kazutaka Murayama,Kazuya Hasegawa,Mi Li,David A. Davis,Eiichi Kodama,Robert Yarchoan,Alexander Wlodawer,Shogo Misumi,Andrew D. Mesecar,Arun K. Ghosh,Hiroaki Mitsuya,Hiroaki Mitsuya +23 more
TL;DR: In this paper, two small-molecule-compounds, named GRL-1720 and 5h, containing an indoline and indole moiety, respectively, which target the SARS-CoV-2 main protease (Mpro), were characterized using in vitro assays and structural analysis.
Journal ArticleDOI
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Shin-ichiro Hattori,Nobuyo Higshi-Kuwata,Jakka Raghavaiah,Debananda Das,Haydar Bulut,David A. Davis,Yuki Takamatsu,Kouki Matsuda,Nobutoki Takamune,Naoki Kishimoto,Tadashi Okamura,Shogo Misumi,Robert Yarchoan,Kenji Maeda,Arun K. Ghosh,Hiroaki Mitsuya,Hiroaki Mitsuya +16 more
TL;DR: GRL-0920 might serve as a potential therapeutic for coronavirus disease 2019 (COVID-19) and might be optimized to generate more-potent anti-SARS-CoV-2 compounds to shed light on the development of therapeutics for CO VID-19.
Journal ArticleDOI
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Kenji Maeda,Masayuki Amano,Yukari Uemura,Kiyoto Tsuchiya,Tomoko Matsushima,Kenta Noda,Yosuke Shimizu,Asuka Fujiwara,Yuki Takamatsu,Yasuko Ichikawa,Hidehiro Nishimura,Mari Kinoshita,Shota Matsumoto,Hiroyuki Gatanaga,Kazuhisa Yoshimura,Shinichi Oka,Ayako Mikami,Wataru Sugiura,Toshiyuki Sato,Tomokazu Yoshida,Shinya Shimada,Hiroaki Mitsuya,Hiroaki Mitsuya +22 more
TL;DR: In this article, the authors examined the effect of BNT162b2-elicited SARS-CoV-2 neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants and the potency of sera against variants of concerns.
Journal ArticleDOI
4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus
Yuki Takamatsu,Yasuhito Tanaka,Satoru Kohgo,Shuko Murakami,Kamalendra Singh,Debananda Das,David Venzon,Masayuki Amano,Nobuyo Higashi-Kuwata,Manabu Aoki,Manabu Aoki,Manabu Aoki,Nicole S. Delino,Sanae Hayashi,Satoru Takahashi,Yoshikazu Sukenaga,Kazuhiro Haraguchi,Stefan G. Sarafianos,Kenji Maeda,Hiroaki Mitsuya,Hiroaki Mitsuya +20 more
TL;DR: Insight is provided on the structural and functional associations of HBV‐ and HIV‐1‐RTs and CAdA may offer new therapeutic options for HBV patients, and molecular modeling suggests that a shallowerHBV‐RT hydrophobic pocket at the polymerase active site can better accommodate the slightly shorter 4′‐cyano of C adenosine‐triphosphate (TP), but not the longer 4‐ethynyl of EFdA‐TP.
Journal ArticleDOI
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
Manabu Aoki,Debananda Das,Hironori Hayashi,Hiromi Aoki-Ogata,Hiromi Aoki-Ogata,Yuki Takamatsu,Arun K. Ghosh,Hiroaki Mitsuya +7 more
TL;DR: Darunavir (DRV) is the only protease inhibitor recommended as a first-line therapeutic and represents the most widely used PI for treating HIV-1-infected individuals and the preexistence of certain single amino acid substitutions such as V32I, I54M, A71V, and I84V in HIV- 1 protease facilitates the development of high-level DRV resistance.